Treatment Options for Covert Hepatic Encephalopathy

被引:0
作者
Nisheet Waghray
Abhijeet Waghray
Kevin Mullen
机构
[1] MetroHealth Medical Center/Case Western Reserve University,Division of Gastroenterology
[2] MetroHealth Medical Center/Case Western Reserve University,Department of Medicine
关键词
Covert hepatic encephalopathy; Minimal hepatic encephalopathy; Non-absorbable disaccharides; Lactulose; Lacitol; Rifaximin; Probiotics; LOLA; Ammonia;
D O I
10.1007/s11938-014-0014-y
中图分类号
学科分类号
摘要
The main issue with treating covert hepatic encephalopathy (HE) is to establish whether it is cost effective to reverse the neuropsychiatric abnormalities that define this mild form of HE. Until fairly recently, covert HE was rarely diagnosed, but advances in computerized psychometric testing have greatly simplified its detection. The many consequences of covert HE are now being identified, and most have been shown to be reversible with standard HE treatment. Perhaps the most enticing possibility will be the potential that standard HE therapies will postpone the onset of overt HE. This will require further evaluation with large placebo-controlled randomized trials.
引用
收藏
页码:229 / 241
页数:12
相关论文
共 103 条
[1]  
Munoz SJ(2008)Hepatic encephalopathy Med Clin N Am 92 795-812
[2]  
Bustamante J(1999)Prognostic significance of hepatic encephalopathy in patients with cirrhosis J Hepatol 30 890-895
[3]  
Prasad S(2007)Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy Hepatology 45 549-559
[4]  
Ferenci P(2002)Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998 Hepatology 35 716-721
[5]  
Zamora Nava LE(2011)Minimal hepatic encephalopathy Ann Hepatol 10 S50-S54
[6]  
Torre Delgadillo A(2011)Editorial: rifaximin and minimal hepatic encephalopathy Am J Gastroenterol 106 317-318
[7]  
Butterworth RF(2000)The prognostic significance of subclinical hepatic encephalopathy Am J Gastroenterol 95 2029-2034
[8]  
Hartmann IJ(2011)Review article: the design of clinical trials in hepatic encephalopathy—an international society for hepatic encephalopathy and nitrogen metabolism (ISHEN) consensus statement Aliment Pharmacol Ther 33 739-747
[9]  
Bajaj JS(2010)Gut flora and hepatic encephalopathy in patients with cirrhosis N Engl J Med 362 1140-1142
[10]  
Riordan SM(1987)Biochemistry and physiology of brain ammonia Physiol Rev 67 440-519